Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $0.06.

  • Amicus Therapeutics' EPS (Basic) rose 40000.0% to $0.06 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.04, marking a year-over-year increase of 8823.53%. This contributed to the annual value of -$0.18 for FY2024, which is 6385.72% up from last year.
  • Latest data reveals that Amicus Therapeutics reported EPS (Basic) of $0.06 as of Q3 2025, which was up 40000.0% from -$0.08 recorded in Q2 2025.
  • Amicus Therapeutics' 5-year EPS (Basic) high stood at $0.06 for Q3 2025, and its period low was -$0.31 during Q4 2021.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.11 (2023), whereas its average is -$0.12.
  • The largest annual percentage gain for Amicus Therapeutics' EPS (Basic) in the last 5 years was 40000.0% (2025), contrasted with its biggest fall of 6000.0% (2025).
  • Quarter analysis of 5 years shows Amicus Therapeutics' EPS (Basic) stood at -$0.31 in 2021, then surged by 37.01% to -$0.19 in 2022, then surged by 43.08% to -$0.11 in 2023, then soared by 144.02% to $0.05 in 2024, then grew by 23.91% to $0.06 in 2025.
  • Its last three reported values are $0.06 in Q3 2025, -$0.08 for Q2 2025, and -$0.07 during Q1 2025.